| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Industry press release |
| Population | Men |
| Source | Marius Pharmaceuticals (GlobeNewswire release via BioSpace) |
| URL | biospace.com/press-releases/marius-pharmaceuticals-applauds-fdas-proposed-testosterone-labeling-updates-as-a-turning-point-for-mens-health (opens in a new tab) |
Specific Claim Evaluated
A cardiovascular outcomes trial of more than 5,200 men found no meaningful increase in major adverse cardiovascular events, and testosterone deficiency is a widespread, undertreated condition.
Primary Research Supporting or Contradicting the Claim
TRAVERSE showed noninferiority for major adverse cardiac events, with more atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
TRAVERSE supports cardiovascular noninferiority in men with confirmed hypogonadism but identified other adverse signals that inform monitoring.
Rationale for Grade
The release describes the label changes as proposals and reports the main cardiovascular result accurately, but omits the adverse signals from the same trial and gives no evidence for its description of deficiency as widespread and undertreated.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"